No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

ACON Exits iiMED Medical Solutions and Completes Full Exit of its IIMAK Investment

Editor: What To Know

  • Headquartered in Amherst, New York, with manufacturing facilities in Mexico, iiMED is a nearshore specialty manufacturer of Class I and Class II consumable medical devices.
  •   “The acquisition of iiMED enables us to continue to scale our platform and enhance our portfolio of solutions to serve our OEM customers.
  • and its affiliates (“ACON”) announced today that it has completed the sale of its equity interests in iiMED Medical Solutions, L.

ACON Investments, L.L.C. and its affiliates (“ACON”) announced today that it has completed the sale of its equity interests in iiMED Medical Solutions, L.L.C. (“iiMED” or the “Company“) to TEAM Technologies, Inc. (“TEAM”). TEAM is backed by affiliates of Clearlake Capital Group, L.P.  Terms of the transaction were not disclosed.

Headquartered in Amherst, New York, with manufacturing facilities in Mexico, iiMED is a nearshore specialty manufacturer of Class I and Class II consumable medical devices. The Company’s target end-markets include patient monitoring, wound care, and compression therapy devices with core capabilities of flame lamination, converting, sewing and clean room assembly.

During ACON’s three-year ownership, iiMED had strong performance and grew approximately 25% year-over-year. “This investment is a great example of ACON’s deep industry expertise and nimbleness, which allowed us to unlock value through a unique carve out strategy,” said Anjali Jolly, a Partner of ACON. “This exit validates our thesis of the strong tailwinds in the medical specialty manufacturing space that are increasingly driven by OEM interest in nearshore partners,” added John Roush, advisor to ACON and Chairman of iiMED’s Board.

Together with ACON’s sale of IIMAK’s industrial business on September 30, 2021, ACON has successfully exited its investment entirely.

“ACON’s experience and resources were instrumental in fueling iiMED’s accelerated organic growth over the past three years. Our partnership with ACON was highly collaborative and critical to our success. We are excited to partner with TEAM to further build upon our exciting growth trajectory,” said Bill Flaherty, CEO of iiMED.

TEAM is a growth-oriented North American engineering solutions and specialty manufacturer serving healthcare end-markets.  “We are excited to welcome iiMED to the TEAM family as we continue expanding our specialty healthcare manufacturing capabilities,” said Marshall White, President and CEO of TEAM.  “The acquisition of iiMED enables us to continue to scale our platform and enhance our portfolio of solutions to serve our OEM customers.  We look forward to working with iiMED’s talented employees to grow our combined businesses.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

VeraClinic: Pioneering Personal Transformation Through Hair Transplantation and Cosmetic Surgery in Turkey

As a testament to Turkey's legacy in the world of aesthetic medicine, VeraClinic invites you to discover the transformative power of our hair transplantation and cosmetic surgery services.

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy